Aier(SZ:300015) Cai Jing Wang·2025-09-19 08:28Core Viewpoint - The aging population in China is driving the demand for presbyopia correction technologies, which include optical correction, surgical correction, and drug treatment. The industry is witnessing rapid development, with both public and private healthcare institutions expanding their services in this area [1][3][4]. Industry Overview - The prevalence of presbyopia treatment methods in China is currently low, indicating that the market is still in its early stages, presenting significant growth potential [3][5]. - The aging population is expected to reach over 400 million by 2035, with more than 40% of the population being elderly by mid-century, leading to an increase in age-related eye diseases [3][4]. Company Developments - 德视佳 reported a 2.8% increase in revenue from presbyopia treatments, reaching 121.4 million HKD in the first half of 2025, while revenue from Presbyond treatment rose from 1.2 million HKD in 2024 to 3.6 million HKD [2][6]. - 爱尔眼科 achieved a revenue of 11.507 billion CNY in the first half of 2025, a 9.12% year-on-year increase, with a net profit of 2.051 billion CNY, reflecting a 0.05% growth [6][7]. - 爱尔眼科 is actively promoting awareness and education regarding presbyopia treatments, anticipating significant market growth driven by the increasing payment capacity and quality demands of the aging population [6][7]. Market Dynamics - The demand for presbyopia treatments is expected to continue rising, with the three-focus lens replacement surgery being identified as the most effective method for addressing this condition [7]. - Despite a decline in net profit for 德视佳 in the first half of 2025, the company remains optimistic about the presbyopia treatment market, viewing it as a key growth driver even in challenging economic conditions [7].